Revolution Medicines opens first line pancreatic cancer trial as Daraxonrasib programme expands

Revolution Medicines has recently begun treating patients in RASolute 303, a global Phase 3 trial testing daraxonrasib in patients with metastatic pancreatic cancer who have not yet received any systemic treatment. The move marks a significant expansion of the company’s clinical programme, taking its lead drug into the front line of one of oncology’s most challenging diseases just days after announcing landmark survival data in previously treated patients.

The trial is testing two distinct approaches simultaneously. One arm evaluates daraxonrasib as a standalone oral therapy. The other tests it in combination with gemcitabine and nab-paclitaxel, the current standard chemotherapy regimen for first-line metastatic pancreatic cancer. Both are being compared head to head against chemotherapy alone, with progression-free survival and overall survival as the primary endpoints.

Alan Sandler, Chief Development Officer at Revolution Medicines, described the initiation as “an important milestone” for the programme, adding that the two treatment strategies represent “biologically rational approaches” to improving patient outcomes in a disease where the bar for progress has historically been extremely low.

Why First-Line Matters

Treating patients earlier in their disease course is generally considered the highest-value opportunity in oncology. Patients who have not yet received systemic therapy tend to be in better overall health, have more treatment options available, and are more likely to respond to novel agents. If daraxonrasib can demonstrate a survival benefit in this setting to match or exceed what was seen in the second-line RASolute 302 trial, the commercial and clinical implications would be substantially larger.

RASolute 303 is also notable for enrolling patients regardless of their specific RAS mutation subtype, reflecting the drug’s design as a broad-spectrum inhibitor of RAS proteins rather than a narrowly targeted therapy.

The Scale of the Problem

The trial addresses a disease of enormous unmet need. Around 60,000 people in the United States are diagnosed with pancreatic cancer each year and approximately 50,000 will die from it. Roughly 80% are diagnosed only once the disease has spread, leaving them with limited options and a five-year survival rate of just 3%. More than 90% of pancreatic cancer cases are driven by RAS mutations, making it the most RAS-dependent of all major cancers and a natural target for daraxonrasib’s mechanism.

Daraxonrasib is now running in four global Phase 3 trials in total, three in pancreatic cancer at different stages of disease and one in non-small cell lung cancer, giving Revolution Medicines one of the most advanced and broad RAS-targeting programmes in the industry.

---

---

Related Topics and Keywords

Biopharma, BiopharmInvesting, clinical trials, Daraxonrasib, FirstLineTreatment, LifeSciences, pancreatic cancer, PDAC, phase3, RASolute303, Revolution Medicines, RVMD